Literature DB >> 8490588

Pharmacokinetics and clinical study of cefotetan in bile: prophylactic use in biliary tract surgery.

P Cherrier1, P Perrin, S Gueye, A M Bosio, P Tinel, P Blot, R Richer, F Fauvelle.   

Abstract

The excretion of cefotetan, a 7 alpha-methoxy-cephalosporin, was studied in 27 patients undergoing biliary surgery. Pharmacokinetic parameters were determined after a single intravenous bolus dose of 1 g (10 patients) or 2 g (17 patients). Rapidly excreted in bile, cefotetan concentrations were considerably higher in bile [range: 92-2,594 mg.l-1 (1 g); 35-4,610 mg.l-1 (2 g)] than in plasma despite the presence of gall stones. Bile bactericidal activities against Staphylococcus aureus (MIC 8 mg.l-1) and Bacteroides fragilis (MIC 2 mg.l-1) correlated well with gall bladder cefotetan levels [r = 0.888 (1 g); r = 0.971 (2 g)]. No cefotetan was detected in the bile of 3 patients with nonfunctioning gall bladders. One other patient with very low activity and these three aside, the inhibitory quotients (cefotetan concentration/MIC) were > 4 for both doses against both bacteria.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490588     DOI: 10.1007/bf01874087

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  14 in total

1.  Effect of biliary obstruction on the hepatic excretion of imipenem-cilastatin.

Authors:  J W Leung; C Y Chan; C W Lai; T C Ko; A F Cheng; G L French
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 2.  Bile sampling, processing and analysis in clinical studies.

Authors:  S M Strasberg; P R Harvey; A F Hofmann
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

3.  The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

Authors:  P D Ellner; H C Neu
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272

4.  The pharmacokinetics of cefotetan excretion in the unobstructed biliary tree.

Authors:  A W Owen; J M Manson; R A Yates; V M Adshead; H L Houghton; D E Tweedle
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

5.  Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers.

Authors:  H K Adam; H L Houghton; R A Yates; J Young; R J Donnelly
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

6.  Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

Authors:  K R Ratzan; C Ruiz; G L Irvin
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

7.  Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile.

Authors:  K R Ratzan; H B Baker; I Lauredo
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Effect of cholecystectomy on gallbladder bile composition.

Authors:  S A Ahrendt; T H Magnuson; H A Pitt; K D Lillemoe
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

9.  Biliary concentrations of piperacillin in patients undergoing cholecystectomy.

Authors:  J A Giron; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

Review 10.  A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.

Authors:  H C Neu
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

View more
  1 in total

1.  Pharmacokinetic differences between the epimers of cefotetan disodium after single intravenous injection in healthy Chinese volunteers.

Authors:  Meng-xiang Su; Min-hong Liu; Bin Di; Li-li Huang; Yuan Jiang; Peng-cheng Ma; Tai-jun Hang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-09-14       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.